menu

KDIGO Conversations in Nephrology: Benefits of RASi Utilization

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

KDIGO Conversations in Nephrology: Benefits of RASi Utilization

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Dr. Clase explains the main evidence-based reasons to use RASi as a cardio-protective therapy and the practical challenges involved. Drs. Pecoits-Filho and Clase also discuss the multiple strategies that can be used for potassium management.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Catherine Clase, MB BChir, BA, MSc, FRCPC
    Nephrologist and Professor of Medicine
    McMaster University
    Editor in Chief 
    Canadian Journal of Kidney Health Disease

    Commercial Interest Speakers Bureau: e-SPACE 

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Dr. Clase explains the main evidence-based reasons to use RASi as a cardio-protective therapy and the practical challenges involved. Drs. Pecoits-Filho and Clase also discuss the multiple strategies that can be used for potassium management.

    This episode is part of the KDIGO Conversations in Nephrology podcast series.
  • Disclosure of Conflicts of Interest

    Roberto Pecoits-Filho, MD, PHD, FACP, FASN, PHD
    Senior Research Scientist
    Arbor Research Collaborative for Health
    Professor of Medicine
    Pontifical Catholic University of Paraná,

    Consulting Fees/Advisory Board: Bayer, AstraZeneca, Akebia, Fibrogen
    Commercial Interest Speakers Bureau: Boehringer Ingelheim, AstraZeneca, Novo Nordisk, Bayer

    Catherine Clase, MB BChir, BA, MSc, FRCPC
    Nephrologist and Professor of Medicine
    McMaster University
    Editor in Chief 
    Canadian Journal of Kidney Health Disease

    Commercial Interest Speakers Bureau: e-SPACE 

  • Provider(s)/Educational Partner(s)

    This episode is jointly provided by KDIGO and Medtelligence

    ReachMD Healthcare ImageReachMD Healthcare Image

  • Commercial Support

    This episode is supported by Vifor Pharma.

Facebook Comments

Schedule19 Oct 2021